BioAtla Inc.

0.44
-0.02 (-3.57%)
At close: Apr 25, 2025, 3:59 PM
0.44
0.11%
After-hours: Apr 25, 2025, 07:01 PM EDT
-3.57%
Bid 0.39
Market Cap 25.7M
Revenue (ttm) 11M
Net Income (ttm) -69.78M
EPS (ttm) -1.44
PE Ratio (ttm) -0.31
Forward PE -0.4
Analyst Hold
Ask 0.45
Volume 751,653
Avg. Volume (20D) 716,516
Open 0.48
Previous Close 0.46
Day's Range 0.42 - 0.47
52-Week Range 0.24 - 3.53
Beta 1.07

About BCAB

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, mel...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 61
Stock Exchange NASDAQ
Ticker Symbol BCAB
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for BCAB stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 581.82% from the latest price.

Stock Forecasts
4 weeks ago
-7.1%
BioAtla shares are trading lower after Citizens Ca... Unlock content with Pro Subscription
1 month ago
-4.92%
BioAtla shares are trading lower after the company announced it is restructuring and realigning resources, which includes a workforce reduction of over 30%.